For preparative chemistry and media development groups that require a defined racemic branched-chain amino acid, DL-isoleucine is supplied as a white to off-white crystalline powder with CAS registry number 443-79-8, molecular formula C₆H₁₃NO₂, and relative molecular mass 131.17 g mol⁻¹. The term DL-isoleucine denotes a 1:1 racemic mixture of D-isoleucine and L-isoleucine, and does not include the diastereomeric D-alloisoleucine and L-alloisoleucine unless separately declared. Commercial grade designations include reagent grade, biochemical grade, and amino acid analyzer calibration grade; the specific catalogue model is manufacturer-dependent. Release specifications for a reagent-grade material generally contain assay by non-aqueous titration with 0.1 mol L⁻¹ perchloric acid between 98.5% and 101.5% on the dried basis, loss on drying not more than 0.20% by USP <731>, residue on ignition not more than 0.10% by USP <281>, chloride not more than 0.020%, sulfate not more than 0.020%, iron not more than 0.001%, and heavy metals not more than 0.001% by USP <231> or an equivalent limit. Identification is confirmed by infrared absorption against a reference spectrum using a potassium bromide disc in an FTIR spectrophotometer; the carboxylate and ammonium deformation bands in the region near 1600 cm⁻¹ and 1500 cm⁻¹ are diagnostic. Optical quality is monitored by polarimetry at 589 nm using a 100 mm cell and a solution concentration of 40 g L⁻¹ in 6 mol L⁻¹ HCl; acceptance is normally −0.5° to +0.5° for the racemate, whereas significant deviations indicate enantiomeric enrichment or contamination by a chiral impurity.

Chemical synthesis of DL-isoleucine via a Strecker condensation of 2-methylbutanal with sodium cyanide and ammonium chloride, followed by acid hydrolysis, yields a mixture of stereoisomers because both the α-carbon and β-carbon centers are formed under non-stereoselective conditions. Industrial isolation of DL-isoleucine therefore requires crystallization protocols that exclude the allo diastereomers by solubility difference or chromatographic separation; the racemic product is crystalline but is not a single chiral entity. The Strecker route is contrasted with a fermentative route for L-isoleucine, which is produced by Corynebacterium glutamicum strains under aerobic fed-batch conditions and is subsequently isolated as the single enantiomer by ion-exchange chromatography or crystallization. Published quantitative process yields for specific production strains are limited, but the racemic material is generally lower cost only when downstream chiral resolution is unnecessary or when the racemate itself is the required reference material.

What Limits Direct Substitution of L-Isoleucine with the Racemate in Mammalian Cell Culture and Nutrition?

Because only the L-enantiomer is aminoacylated by eukaryotic aminoacyl-tRNA synthetases and incorporated into polypeptide chains, the racemate cannot be regarded as a metabolically equivalent drop-in for L-isoleucine in mammalian cell culture or monogastric nutrition. In a chemically defined medium designed for Chinese hamster ovary cells, substitution of L-isoleucine by DL-isoleucine on an equal-mass basis delivers only approximately 50% biologically available L-isoleucine if the cell line lacks D-amino acid oxidase or racemase activity; published data for specific cell lines are limited, and dose verification should be performed with spent-media amino acid analysis by ion-exchange chromatography with post-column ninhydrin detection according to ISO 13903:2005 or an equivalent validated method. The D-enantiomer may compete for amino acid transport at the sodium-independent system L carrier, but transport kinetics are stereoselective and variable across species and tissue origin. Where a fermentation process uses a bacterial auxotroph that requires L-isoleucine, the racemate is typically screened only after chiral purity and D-isoleucine content are controlled, because the biologically relevant concentration of L-isoleucine is one-half of the added mass.

In solid-phase peptide synthesis, the use of DL-isoleucine as a raw material is generally restricted to preparation of racemic standards or structure-activity relationship studies. Preparation of N-protected derivatives such as N-tert-butoxycarbonyl-DL-isoleucine is undertaken under Schotten-Baumann conditions with pH maintained between 9.0 and 10.5 using a pH-stat and sodium hydroxide. Coupling of the racemate in solid-phase synthesis produces diastereomeric peptides that must be resolved by reversed-phase HPLC with a C18 column and an acetonitrile/ammonium formate gradient; under these conditions the L-isoleucyl and D-isoleucyl peptides may co-elute unless a chiral column is used. Laboratories performing chiral purity verification commonly derivatize with ortho-phthaldialdehyde plus N-isobutyryl-L-cysteine and separate the resulting diastereomeric isoindoles on a C18 column with fluorescence detection at excitation 340 nm and emission 450 nm. Sub-percent detection is attainable with careful mobile-phase optimization, but the limit of quantitation must be established for each detector and column configuration.

Enzyme-mediated resolution of DL-isoleucine begins with acetylation of the racemate using acetic anhydride under alkaline pH. N-acetyl-DL-isoleucine is then subjected to acylase I from porcine kidney at pH 7.5 and 37 °C. The reaction selectively deacetylates the L-enantiomer, producing free L-isoleucine and N-acetyl-D-isoleucine; the two products are separated by precipitation or cation-exchange chromatography. This route is used when a process requires enantiopure L-isoleucine from the racemate; the residual N-acetyl-D-isoleucine may be racemized under acetic anhydride conditions and recycled. Kinetic parameters such as conversion at 4 h are enzyme-lot dependent; therefore, design-of-experiment studies in a stirred reaction calorimeter are required before scale-up.

When the Racemate Is Added to Microbial Production Media, Sterilization and Solubility Must Be Considered

In bacterial fermentation, DL-isoleucine is often added as a solid before heat sterilization or as a sterile-filtered solution after autoclaving. Solubility in water is pH dependent; below the carboxyl pKa of approximately 2.36 the cationic form predominates, and above the amino pKa of approximately 9.68 the anionic form dominates, both of which increase solubility relative to the zwitterionic form near pH 5.5–6.5. A concentrated stock solution prepared at 20 g L⁻¹ may remain partly undissolved in the zwitterionic range; complete dissolution should be confirmed in a controlled-temperature vessel at 25 °C with a 0.45 µm membrane filtration step before aseptic addition. Heat sterilization at 121 °C for 15 min in the presence of reducing sugars can induce Maillard-derived browning and reduce available amino nitrogen; therefore, the amino acid is preferably sterilized separately or added after the carbohydrate solution has cooled to below 80 °C.

Vendor Specification Profile and Typical Release Limits

In dry blending of amino acid premixes, batch-to-batch variance in tapped bulk density and particle size distribution affects segregation in a double-cone blender. A typical specification may require 95% passage through a 60 mesh sieve and tapped bulk density between 0.35 g cm⁻³ and 0.65 g cm⁻³; the exact range must be taken from the supplier certificate because the material is not a directly fluid-bed granulated product. Segregation can be minimized by using a bin blender with a fill volume between 50% and 70% and an intensifier bar speed below 150 rpm, but the acceptable operating envelope is equipment-specific. When DL-isoleucine is blended with L-isoleucine, L-valine, and L-leucine for branched-chain amino acid analysis standards, the blend should be assayed by HPLC after derivatization to confirm the nominal content because hygroscopic caking can cause local agglomerates. Storage in low-density polyethylene bags inside sealed aluminium-lined drums at 20–25 °C and relative humidity below 40% is recommended; exposure to high humidity increases caking without necessarily increasing loss on drying above 0.2%.

Solubility in Aqueous Process Streams Depends on pH and Temperature

Solution preparation for continuous chromatography or bioconversion should account for the zwitterionic equilibrium. At a temperature of 25 °C, a racemate suspension in water generates a conductivity that is dominated by the partial dissociation of the carboxyl and ammonium groups; pH adjustment with 1 mol L⁻¹ hydrochloric acid to pH 2.0 or with 1 mol L⁻¹ sodium hydroxide to pH 9.5 increases dissolved fraction and reduces the need for extended mixing. A jacketed stirred vessel with a retreat-curve impeller operating at 150–250 rpm provides adequate dispersion for laboratory-scale preparation up to 100 L. Filtration through a 0.22 µm polyethersulfone membrane is used when the solution is to be transferred into a bioreactor; membrane fouling is lower when the pH is held below 3.0 or above 9.0 because the zwitterionic precipitate is minimized. Published data for specific solubility maxima in binary water-ethanol or water-acetone systems are limited; process development groups are advised to generate solubility curves by gravimetric method using a thermostatic shaker bath and 0.45 µm syringe filtration before scaling to production.

For analytical reference work, the principal differences are not cosmetic but are defined by stereochemistry and optical rotation. L-Isoleucine has CAS registry number 73-32-5 and is the proteinogenic branched-chain amino acid found in mammalian proteins; D-Isoleucine has CAS registry number 319-78-8 and is its mirror image; DL-isoleucine is the racemic mixture with CAS registry number 443-79-8. L-Alloisoleucine is a diastereomer of L-isoleucine that appears in plasma during maple syrup urine disease and is resolved by the same OPA chiral-thiol derivatization protocols. In cation-exchange amino acid analysis, L-isoleucine and L-alloisoleucine are separated under optimized lithium buffer gradients at column temperatures between 30 °C and 70 °C; the racemate cannot be used as a single reference for that separation because it contains only the isoleucine enantiomers and not necessarily the allo forms.